Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Experts will explore AI-driven healthcare innovation and strategies to enhance patient engagement DIA, a global non-profit organization of life sciences professionals, will unite stakeholders from ...

Elsewhere, Stoboclo and Osenvelt have received regulatory endorsements in the European Union and Korea. Amgen’s Prolia and Xgeva were initially approved in 2010 to treat osteoporosis and ...

In its Thousand Oaks hometown in California, it was far and away the biggest employer, with 1 in 10 of the town folk working for Amgen. It built sites throughout Europe and Asia, and became even ...

A closing highlight of the programme is the joint symposium for all European Amgen Scholars in Cambridge, UK. In addition to conducting hands-on research, you will attend workshops and events offering ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

Continued strong commercial execution of the OGSIVEO launch in the U.S. with fourth quarter and full-year 2024 U.S. net ...

A new study led by researchers from Boston University Chobanian & Avedisian School of Medicine has found there is no consensus in how clinical experts interpret CGM reports from people without ...

Trump has set the European Union as his next target ... Top executives at big branded drugmakers including Merck, Amgen and Bristol-Myers said this week the impact of the 10% China tariffs on them ...

Google’s parent company and other tech stocks are weighing on a mixed Wall Street Wednesday as the focus swings back toward how much profit businesses are making.

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...